There is a huge unmet need for the development of treatments that target the underlying causes of neurodegenerative diseases. To address the high failure rates and low investment returns of traditional neuroscience R&D approaches, companies are increasingly adopting alternative R&D business models that focus on collaboration and shared expertise. Discover how AstronauTx and Talisman Therapeutics are using collaborative approaches to discover potential new ways to treat neurological disease in the future.